Австралія - англійська - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium nitroprusside, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - sodium nitroprusside baxter concentrated injection is indicated for:,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate.,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Ізраїль - англійська - Ministry of Health

lapidot medical import and marketing ltd - sodium chloride - solution for injection - sodium chloride 9 mg/ml - sodium chloride - sodium chloride - short - term intravascular volume substitution. hypotonic dehydration or isotonic dehydration.vehicle solution for supplementary medication.fluid and electrolyte replacement, hypochloremic alkalosis and chloride losses.externally for wound irrigation and moistening of wound tamponade dressings.

Ізраїль - англійська - Ministry of Health

lapidot medical import and marketing ltd - sodium chloride - solution for injection - sodium chloride 0.9 g / 100 ml - sodium chloride - sodium chloride - short - term intravascular volume substitution. hypotonic dehydration or isotonic dehydration.vehicle solution for supplementary medication.fluid and electrolyte replacement, hypochloremic alkalosis and chloride losses.externally for wound irrigation and moistening of wound tamponade dressings.

Ізраїль - англійська - Ministry of Health

lapidot medical import and marketing ltd - sodium chloride - solution for injection - sodium chloride 0.9 g / 100 ml - sodium chloride - sodium chloride - short - term intravascular volume substitution. hypotonic dehydration or isotonic dehydration.vehicle solution for supplementary medication.fluid and electrolyte replacement, hypochloremic alkalosis and chloride losses.externally for wound irrigation and moistening of wound tamponade dressings.

Ізраїль - англійська - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - sodium nitroprusside - injection, concentrated - excipient ingredients: water for injections - - immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside. - producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate. - short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - valwok is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - valwok is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

США - англійська - NLM (National Library of Medicine)

allergan, inc. - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 7 mg - namenda xr®  is indicated for the treatment of moderate to severe dementia of the alzheimer’s type. namenda xr is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. risk   summary   there are no adequate data on the developmental risk associated with the use of namenda xr in pregnant women.  adverse developmental effects (decreased body weight and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. these doses are higher than those used in humans at the maximum recommended daily dose of namenda xr [see   data].    in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal   data oral administration of memantine 

США - англійська - NLM (National Library of Medicine)

allergan, inc. - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t), donepezil hydrochloride (unii: 3o2t2pj89d) (donepezil - unii:8ssc91326p) - memantine hydrochloride 14 mg - namzaric is indicated for the treatment of moderate to severe dementia of the alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. namzaric is contraindicated in patients with known hypersensitivity to memantine hydrochloride, donepezil hydrochloride, piperidine derivatives, or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of namzaric or its active ingredients (memantine hydrochloride and donepezil hydrochloride) in pregnant women. adverse developmental effects (mortality and decreased body weight and skeletal ossification) were observed in the offspring of rats administered memantine or donepezil during pregnancy at doses associated with minimal maternal toxicity. these doses are higher than those used in humans at the recommended daily dose of namzaric [see data ] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recogni